TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02855866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cortisone aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Study: NCT02973347

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent enteral feeding
Description: The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous enteral feeding
Description: The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
Study: NCT02313675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00831688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Meniett(C) device by MedTronic
Description: pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
Study: NCT02260024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high caloric meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole IR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2B
Study: NCT02368041

Intervention type: DEVICE
Intervention: InSpectraTM StO2 monitor
Description: InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
Study: NCT00003459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
Study: NCT01785446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of dexmedetomidine on cisatracurium and sufentanil consumption
Description: In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
Study: NCT04353375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
Study: NCT03660202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firesorb
Description: Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
Study: NCT01663116

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: 1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15
Study: NCT04176198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusivertib
Description: Oral PIM Inhibitor
Study: NCT01663116

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15
Study: NCT04167059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered participation strategies to increase physical activity
Description: Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered participation strategies to increase physical activity
Description: Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
Study: NCT04425161

Intervention type: OTHER
Intervention: Fluid challenge (0.9 % NaCl)
Description: 500 ml Fluid challenge of (0.9 % NaCl) will be given

Intervention type: OTHER
Intervention: Fluid challenge (0.9 % NaCl)
Description: 500 ml Fluid challenge of (0.9 % NaCl) will be given
Study: NCT02364973

Intervention type: OTHER
Intervention: PET-MRI
Description: The study patients undergo positron emission tomography (PET) after informed consent is obtained
Study: NCT01295502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00859053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-790052
Description: Capsules, Oral, 30 mg, single dose, one day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-790052
Description: Capsules, Oral, 30 mg, single dose, one day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-790052
Description: Capsules, Oral, 30 mg, single dose, one day
Study: NCT04176198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusivertib
Description: Oral PIM Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral JAK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Oral JAK inhibitor
Study: NCT03217422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control with conversion to active VAY736
Study: NCT00859053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-790052
Description: Capsules, Oral, 30 mg, single dose, one day
Study: NCT01114178

Intervention type: OTHER
Intervention: questionnaire
Description: self completed questionnaire supervised by a technician
Study: NCT04392947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: MagVenture Coil Cool B70 A/P

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: MagVenture Coil Cool B70 A/P without TMS being actively delivered
Study: NCT03708224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV
Study: NCT03618771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
Study: NCT02710981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil vaginal gel
Description: In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
Study: NCT00694837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir
Description: The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
Study: NCT00328887

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD40 Gene Transfer
Description: gene transfer, intratumoral administration
Study: NCT04240041

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcerebellar diamater
Description: Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.

Intervention type: DIAGNOSTIC_TEST
Intervention: Placental thickness
Description: Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
Study: NCT02745704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa
Description: peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
Study: NCT03516773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB612 (EBP05)
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB612 (EBP05)
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB612 (EBP05)
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB612 (EBP05)
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NATPARA/NATPAR
Description: A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
Study: NCT02813096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folfox4 chemotherapy regimen
Description: Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops.
Study: NCT02287818

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily from Day 1 to Week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201
Description: AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
Study: NCT02813096

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops.
Study: NCT05337111

Intervention type: OTHER
Intervention: Cardiorespiratory fitness test
Description: Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness

Intervention type: OTHER
Intervention: Cardiorespiratory fitness test
Description: Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness

Intervention type: OTHER
Intervention: Cardiorespiratory fitness test
Description: Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness

Intervention type: OTHER
Intervention: Resting measure of fat oxidation
Description: Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest

Intervention type: OTHER
Intervention: Resting measure of fat oxidation
Description: Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest

Intervention type: OTHER
Intervention: Resting measure of fat oxidation
Description: Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
Study: NCT00869895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
Study: NCT04161989

Intervention type: DRUG
Group type: OTHER
Intervention: omega-3 fatty acids
Description: . The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.

Intervention type: DRUG
Group type: OTHER
Intervention: omega-3 fatty acids
Description: . The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.

Intervention type: DRUG
Group type: OTHER
Intervention: vaginal progesterone
Description: Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
Study: NCT02706470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone
Description: Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
Study: NCT03998033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET140202 autologous T cell product
Description: Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
Study: NCT01235247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reminders vs. no reminders
Description: Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
Study: NCT02061267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The subjects will receive a vitamin B3 supplement (2 g)
Study: NCT05337111

Intervention type: OTHER
Intervention: Maximum fat oxidation test
Description: Progressive exercise test to determine maximum fat oxidation during exercise

Intervention type: OTHER
Intervention: Maximum fat oxidation test
Description: Progressive exercise test to determine maximum fat oxidation during exercise

Intervention type: OTHER
Intervention: Maximum fat oxidation test
Description: Progressive exercise test to determine maximum fat oxidation during exercise
Study: NCT03379259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A333
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A333
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A333
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A333
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: Anti-PD-1 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: Anti-PD-1 antibodies
Study: NCT00473668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilbrix-Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/ Hiberix™
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/ Hiberix™
Description: Intramuscular injection, 1 dose
Study: NCT02061267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The subjects will receive a vitamin B3 supplement (2 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The subjects will receive a vitamin B3 supplement (2 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The subjects will receive a vitamin B3 supplement (2 g)
Study: NCT00654836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
Study: NCT02061267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated meal
Description: Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated meal
Description: Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
Study: NCT01785446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of dexmedetomidine on cisatracurium and sufentanil consumption
Description: In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of cisatracurium and sufentanil in different age groups.
Description: For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.